Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment

Fig. 5

a Clonogenic survival of p53-mutant glioblastoma cell lines after fractionated single drug treatment with SAR, 5-aza-dC, and TMZ with or without irradiation (7 × 2.2 Gy, total dose 15.4 Gy). b Representative photographs of stained colonies after clonogenic assay. Concentrations were as follows: 0.25 μM SAR, 0.5 μM 5-aza-dC, 50 μM TMZ. Numbers indicate seeded cells per well. c Clonogenic survival after fractionated single drug treatment of p53-mutant glioblastoma cell lines with CCT244747. a, c Data are means ± SEM from 3 independent experiments. d Surviving fractions (means ± SEM) of p53-mutant glioblastoma cell lines after treatment with CCT244747 or SAR020106 and/or IR. e Overall surviving fraction of p53-mutant, primary P0297 cells. Data are means ± SEM from one experiment in sextuplicates. a, c, e Statistical significance compared to untreated, unirradiated control is calculated by Mann-Whitney test and indicated by asterisks (*, p ≤ 0.05; **, p ≤ 0.01). All irradiated groups are significantly different compared to untreated, non-irradiated control (p ≤ 0.05) and therefore no further labeling is shown. Statistical significance compared to untreated, irradiated control is indicated by hashtag (#, p ≤ 0.05)

Back to article page